{"id":"W4386024076","doi":"10.1097/01.hs9.0000967492.06443.0a","title":"S145: VENETOCLAX-OBINUTUZUMAB FOR PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA: 6-YEAR RESULTS OF THE RANDOMIZED CLL14 STUDY","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Obinutuzumab; Venetoclax; Medicine; Chronic lymphocytic leukemia; Internal medicine; Tolerability; Chlorambucil; Bendamustine; Oncology; Hazard ratio; Interquartile range; Clinical endpoint; Leukemia; Gastroenterology; Randomized controlled trial; Cyclophosphamide; Chemotherapy; Adverse effect; Confidence interval","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005346392,0.00072171,0.001936646,0.000428357,0.0003681096,0.001370179,0.0007407928,0.001987977,0.006415844],"category_scores_gemma":[0.004796871,0.0003145573,0.00323794,0.0005785443,0.000478081,0.0008010719,0.0005706202,0.001924991,0.001164994],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008596879,"about_ca_system_score_gemma":0.001321425,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009221486,"about_ca_topic_score_gemma":0.001845791,"domain_scores_codex":[0.9973303,0.00193596,0.0001648971,0.0001702636,0.0002204018,0.000178111],"domain_scores_gemma":[0.9961628,0.001108042,0.00114657,0.000294,0.0004112842,0.0008773474],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9171126,0.004326583,0.00607045,0.001248705,0.003538109,0.00006921249,0.00007387288,0.0005989562,0.002660897,0.0002085494,0.006837138,0.0572549],"study_design_scores_gemma":[0.8571014,0.1022014,0.02543477,0.0003290409,0.003831429,0.0001521125,0.00005260795,0.0005703716,0.0007613006,0.0002957836,0.009227969,0.00004185097],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9364039,0.03410544,0.001335015,0.003311514,0.001004734,0.005048232,0.01223372,0.0002324973,0.00632482],"genre_scores_gemma":[0.9541492,0.009549378,0.002518298,0.004240468,0.001322491,0.005030543,0.01621024,0.00009022001,0.00688909],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006415844,"threshold_uncertainty_score":0.02827471,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02367475763571688,"score_gpt":0.3104929278816977,"score_spread":0.2868181702459809,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}